Finance

Beta
Lists
RGEDF:OTCMKTS
Gedeon Richter Ord Shs
$38.84
-7.07%
(-2.96) 1D
Jun 3, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RGEDF...
Open
$38.84
High
$38.84
Low
$38.84
Avg. vol.
82.00
Volume
1.00
52-wk high
$45.28
52-wk low
$29.00
Beta
11.98
Shares outstanding
186.38M
No. of employees
11K
Open
$38.84
High
$38.84
Low
$38.84
Avg. vol.
82.00
Volume
1.00
52-wk high
$45.28
52-wk low
$29.00
Beta
11.98
Shares outstanding
186.38M
No. of employees
11K
News stories
From sources across the web
Profile
Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with a direct presence in the United Kingdom, Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries. Gedeon Richter Plc. has a primary listing on the Budapest Stock Exchange and is a constituent of the BUX Index. It had a market capitalisation of approximately $6.6 billion as of 2018, the third largest of companies with a primary listing on the Budapest Stock Exchange. It has secondary listings on the Luxembourg Stock Exchange. Richter sells products for the neuroscience, oncology, women's health and cardiovascular therapeutic areas among others. The company is also active in biosimilar product development. The company was established in Budapest by Gedeon Richter, a pharmacist, in 1901. Wikipedia
About Gedeon Richter Ord Shs
CEOGábor Orbán
Employees11.2K
Founded1901
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in HUF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in HUF
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
241.48B
214.69B
248.76B
220.20B
Cost of goods sold
80.91B
62.75B
86.50B
72.45B
Cost of revenue
80.91B
62.75B
86.50B
72.45B
Research and development expenses
25.10B
19.47B
22.86B
22.85B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
58.98B
52.30B
52.27B
55.32B
Operating expense
86.88B
88.86B
67.38B
80.38B
Total operating expenses
167.79B
151.62B
153.88B
152.84B
Operating income
73.70B
63.07B
94.88B
67.37B
Other non operating income
4.16B
2.30B
-2.50B
-
EBT including unusual items
63.08B
52.10B
87.59B
78.78B
EBT excluding unusual items
64.14B
51.04B
93.91B
78.78B
Income tax expense
11.14B
8.66B
18.91B
13.30B
Effective tax rate
17.66%
16.63%
21.59%
16.89%
Other operating expenses
2.80B
17.10B
-11.00B
2.21B
Net income
51.84B
43.35B
69.01B
65.28B
Net profit margin
21.47%
20.19%
27.74%
29.65%
Earnings per share
-
-
-
-
Interest and investment income
35.01B
6.00B
11.63B
26.16B
Interest expense
-46.47B
-3.60B
-10.52B
-15.63B
Net interest expenses
-11.46B
2.40B
1.10B
10.52B
Depreciation and amortization charges
-
-
-
-
EBITDA
85.49B
81.50B
104.28B
83.47B
Gain or loss from assets sale
-
-
1.41B
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more